Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.73 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776962 | 0.80 | NOTUM (1.00) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL19398295 | 0.79 | ALDH1A1 (0.54) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL15872005 | 0.79 | NOTUM (0.72) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL19398293 | 0.78 | NOTUM (0.52) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL21849244 | 0.77 | KMT2A (0.43) | NOTUMALDH1A1LMNAHTTAR | |
| SCHEMBL19398291 | 0.76 | KMT2A (0.55) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL14243215 | 0.76 | NOTUM (0.72) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL14228219 | 0.75 | NOTUM (0.66) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL10022446 | 0.75 | NOTUM (0.66) | NOTUMF2ALDH1A1MAPTLMNA | |
| SCHEMBL2054614 | 0.73 | NOTUM (0.58) | NOTUMF2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | NOTUM 4732/4885F2 4829/4885ALDH1A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.